PTGX – protagonist therapeutics, inc. (US:NASDAQ)
Stock Stats
News
5/8
02:42 pm
ptgx
Low
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at JMP Securities from $42.00 to $45.00. They now have a "market outperform" rating on the stock.
5/7
04:27 pm
ptgx
Medium
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event [Yahoo! Finance]
5/7
04:19 pm
ptgx
Medium
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/7
04:10 pm
ptgx
Medium
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
5/7
04:05 pm
ptgx
Low
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/7/2024
04:05 pm
PTGX
5.1%
BEAT
8/3/2023
04:05 pm
PTGX
3.3%
MISS
5/8
02:08 pm
Maintains
Market Outperform
Market Outperform
JMP Securities
Medium
3.0%
5/8
02:08 pm
Maintains
Market Outperform
Market Outperform
JMP Securities
Medium
3.0%
3/11
10:11 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
-1.1%
3/11
10:11 am
Reiterates
Market Outperform
Market Outperform
JMP Securities
Low
-1.1%
2/28
09:48 am
Maintains
Overweight
Overweight
JP Morgan
Low
0.6%
5/7
04:52 pm
ptgx
Medium
Form 10-Q Protagonist Therapeutics For: Mar 31
5/7
04:29 pm
ptgx
Medium
Form 8-K Protagonist Therapeutics For: May 07
4/26
04:44 pm
ptgx
Low
Form ARS Protagonist Therapeutics For: Dec 31
4/26
04:39 pm
ptgx
Low
Form DEFA14A Protagonist Therapeutics
4/26
04:31 pm
ptgx
Low
Form DEF 14A Protagonist Therapeutics For: Jun 20
Show more
Top News Gainers
12/3 Form 4 Protagonist Therapeutics For: Dec 03 Filed by: PATEL DINESH V PH D 70.0%
3/12 Form 4 Protagonist Therapeutics For: Mar 12 Filed by: SELICK HAROLD E 18.3%
5/8 Form 10-Q Protagonist Therapeutics For: Mar 31 16.7%
3/18 Form 8-K Protagonist Therapeutics For: Mar 13 10.9%
10/30 Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera 8.1%
8/17 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.8%
9/25 Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2 7.1%
8/20 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.6%
5/8 Q1/2019 3/31/2019 EPS -0.580 ZacksConsensus -0.640 ActVsEst 0.060 - Beat 6.2%
11/9 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 4.3%
Top News Decliners
12/3 Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia -46.7%
11/6 Form 10-Q Protagonist Therapeutics For: Sep 30 -14.4%
11/25 Form EFFECT Protagonist Therapeutics -11.9%
5/7 Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 -11.1%
11/26 Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug [Seeking Alpha] -7.7%
3/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -7.3%
3/12 Protagonist Therapeutics Inc (NASDAQ: PTGX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.50 price target on the stock. -6.7%
3/10 Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.2%
11/6 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.8%
7/25 Protagonist Therapeutics Inc (NASDAQ: PTGX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -4.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3